HOME >> BIOLOGY >> NEWS
Junk DNA yields new kind of gene

BOSTON-In a region of DNA long considered a genetic wasteland, Harvard Medical School researchers have discovered a new class of gene. Most genes carry out their tasks by making a product-a protein or enzyme. This is true of those that provide the body's raw materials, the structural genes, and those that control other genes' activities, the regulatory genes. The new one, found in yeast, does not produce a protein. It performs its function, in this case to regulate a nearby gene, simply by being turned on.

Joseph Martens, Lisa Laprade, and Fred Winston found that by switching on the new gene, they could stop the neighboring structural gene from being expressed. "It is the active transcription of another gene that is regulating the process," said Martens, HMS research fellow in genetics and lead author of the June 3 Nature study .

"I cannot think of another regulatory gene such as this one," said Winston, HMS professor of genetics. The researchers have evidence that the new gene, SRG1, works by physically blocking transcription of the adjacent gene, SER3. They found that transcription of SRG1 prevents the binding of a critical piece of SER3's transcriptional machinery.

The discovery raises tantalizing questions. How does this gene-blocking occur? Do other regulatory genes work in this fashion? Does the same mechanism occur in mammals, including humans?

At the same time, SRG1 provides clues to a recent puzzle. Researchers have lately begun to suspect that the long stretches of apparently useless, or junk, DNA might possess a hidden function. In the past year, evidence has been pouring in, not just from yeast but from mammals, that these apparently silent regions produce RNAs, which are associated with transcriptional activity (see Focus, March 5, 2004 http://focus.hms.harvard.edu/2004/March5_2004/biological_chemistry.html). Yet no one has found associa
'"/>

Contact: Judith Montminy / Misia Landau
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
2-Jun-2004


Page: 1 2 3 4

Related biology news :

1. Alaska scientists find Arctic tundra yields surprising carbon loss
2. Heart gene yields insights into evolution, disease risk
3. A genetic disorder yields insight into genes and cognition
4. Two-month study of life in mid-Atlantic yields trove of species, new insights & questions
5. Whale carcass yields bone-devouring worms
6. Study yields insights into precancerous condition
7. Water study yields a few surprises for New England
8. Access to DNA secrets yields better understanding of genes, possible tool for disease diagnosis
9. Mouse study yields clue to why liver is less prone to rejection, say Pitt researchers
10. Microbial biofilm yields community genomes, metabolic clues
11. Map of genes in plant root yields new tool for exploring tissue development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Junk DNA yields new kind gene

(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: